<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="editorial" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">893384</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.893384</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Targeting Neuro-Immuno-Vascular Interactions in the Brain and the Periphery</article-title>
<alt-title alt-title-type="left-running-head">Wilhelm et al.</alt-title>
<alt-title alt-title-type="right-running-head">Editorial: Neuro-Immune-Vascular Interactions</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wilhelm</surname>
<given-names>Imola</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/820401/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krizbai</surname>
<given-names>Istv&#xe1;n A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1033997/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gherghiceanu</surname>
<given-names>Mihaela</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/458598/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sz&#x151;ke</surname>
<given-names>&#xc9;va</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/846198/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Helyes</surname>
<given-names>Zsuzsanna</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/488917/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Institute of Biophysics</institution>, <institution>Biological Research Centre</institution>, <addr-line>Szeged</addr-line>, <country>Hungary</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Victor Babe&#x219; National Institute of Pathology (INCDVB)</institution>, <addr-line>Bucharest</addr-line>, <country>Romania</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Pharmacology and Pharmacotherapy</institution>, <institution>Medical School and Szent&#xe1;gothai Research Centre</institution>, <institution>University of P&#xe9;cs</institution>, <addr-line>P&#xe9;cs</addr-line>, <country>Hungary</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited and reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/20178">Frontiers Editorial Office</ext-link>, Frontiers Media SA, Switzerland</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Imola Wilhelm, <email>wilhelm.imola@brc.hu</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>893384</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>03</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>03</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Wilhelm, Krizbai, Gherghiceanu, Sz&#x151;ke and Helyes.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Wilhelm, Krizbai, Gherghiceanu, Sz&#x151;ke and Helyes</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" journal-id="Front. Pharmacol." xlink:href="https://www.frontiersin.org/researchtopic/11817" ext-link-type="uri">Editorial on the Research Topic <article-title>Targeting Neuro-Immuno-Vascular Interactions in the Brain and the Periphery</article-title>
</related-article>
<kwd-group>
<kwd>neuroinflammation</kwd>
<kwd>inflammasome</kwd>
<kwd>pain</kwd>
<kwd>neuropathy</kwd>
<kwd>ischemic stroke</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Complex neuro-immune-vascular interactions play key roles in the development of both neuroinflammation (an inflammatory response within the nervous system) and neurogenic inflammation (sensory nerve-released neuropeptides inducing inflammation in different tissues). Both phenomena have a substantial importance in the pathogenesis of several diseases and might be targets for pharmacological interventions.</p>
<p>Therefore, the present Research Topic was designed to collect papers on the molecular mechanisms and pharmacology of pathological processes affecting neuro-immune-vascular interfaces, focusing on neurodegeneration, stroke, headache, neuropathic and other types of pain, as well as peripheral inflammatory diseases, such as arthritis or dermatitis. In addition, interactions between the peripheral and central nervous systems have also been explored.</p>
<p>Neuroinflammation is usually accompanied by vascular reactions, including opening of the blood-brain barrier. In the present Research Topic, <xref ref-type="bibr" rid="B2">Gabbert et al. (2020)</xref> describe the important role of protocadherins, especially PcdhgC3 in regulating the barrier integrity of brain microvascular endothelial cells in control and inflammatory conditions. One of the most frequent inflammatory conditions affecting brain vessels is ischemic stroke. Recanalization with tissue plasminogen activator (tPA) is the only approved agent available in this condition. The systematic review by <xref ref-type="bibr" rid="B9">Ye et al. (2020)</xref> identifies the possible protective effect of immunomodulators on a lethal side effect of tPA treatment, namely hemorrhagic transformation. In addition, <xref ref-type="bibr" rid="B1">Chen et al. (2021)</xref> found that inflammasome proteins were upregulated in neutrophil extracellular traps present in thrombi of patients with acute ischemic stroke, contributing to poor outcomes after tPA treatment.</p>
<p>Inflammasomes were in the focus of the work of <xref ref-type="bibr" rid="B6">N&#xf3;gr&#xe1;di et al. (2020)</xref> as well. However, they studied not vascular cells, but neurons and found that peripheral nerve injury induced inflammasome activation in motoneurons. The thiazide structure oral antidiabetic diazoxide proved to be protective in this model. Interlocking of peripheral and central processes has been investigated by <xref ref-type="bibr" rid="B4">Lovren&#x10d;i&#x107; et al. (2020)</xref> too. They found that intranasal inflammatory reactions provoke distant intracranial changes, including headache.</p>
<p>Inflammatory reactions may affect the peripheral nervous system as well. Inflammatory neuropathies are characterized by leukocyte infiltration of peripheral nerves, demyelination and axonal degeneration. Therefore, inflammation and pain control in chronic neuropathies is essential to improve the outcomes of the disease. Somatostatin released from capsaicin-sensitive peptidergic sensory nerve endings leads to anti-inflammatory and anti-hyperalgesic actions at distant parts of the body, through activation of the somatostatin receptor subtype 4 (SST4). Based on this knowledge, <xref ref-type="bibr" rid="B3">K&#xe1;nt&#xe1;s et al. (2021)</xref> demonstrated the anti-nociceptive actions of orally active novel pyrollo-pyrimidine SST4 agonists, which are promising drug candidates in neuropathic pain.</p>
<p>A specific subgroup of neuropathies, immune axonal neuropathies are described in the review of <xref ref-type="bibr" rid="B8">Tulb&#x103; et al. (2021)</xref>. These immune-mediated neuropathies occasionally accompany autoimmune rheumatic diseases, which in turn may also have cardiovascular comorbidities. These latter conditions have been explored by <xref ref-type="bibr" rid="B5">Mong et al. (2020)</xref>, who found that arterial aging is faster in rheumatoid arthritis patients than in control subjects, and inhibiting inflammation is essential to attenuate the associated cardiovascular risk.</p>
<p>Finally, the paper of <xref ref-type="bibr" rid="B7">Sz&#xf6;ll&#x151;si et al. (2022)</xref> reviews a symptom arising from cutaneous immune-neuronal crosstalks, i.e., pruritus or itch, which may involve the excitation of itch-sensitive neurons or damage of the itch-processing neural network.</p>
<p>Altogether, as a result of the common effort of the Frontiers in Pharmacology team and the five guest editors, a balanced collection of original and review papers have been included in the Research Topic. Nine articles originating from six different countries cover a wide thematic range focused around inflammatory processes affecting the central and peripheral nervous systems.</p>
</body>
<back>
<sec id="s1">
<title>Author Contributions</title>
<p>IW drafted the paper. All authors read and approved the final version.</p>
</sec>
<sec sec-type="COI-statement" id="s2">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s3">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>X. O.</given-names>
</name>
<name>
<surname>Ferrer Marcelo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>V. W.</given-names>
</name>
<name>
<surname>Blackwelder</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Yavagal</surname>
<given-names>D. R.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Netosis and Inflammasomes in Large Vessel Occlusion Thrombi</article-title>. <source>Front Pharmacol.</source> <volume>11</volume>, <fpage>607287</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.607287</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabbert</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dilling</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meybohm</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Burek</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Deletion of Protocadherin Gamma C3 Induces Phenotypic and Functional Changes in Brain Microvascular Endothelial Cells In Vitro</article-title>. <source>Front Pharmacol.</source> <volume>11</volume>, <fpage>590144</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.590144</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>K&#xe1;nt&#xe1;s</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sz&#xf6;ke</surname>
<given-names>&#x00C9;.</given-names>
</name>
<name>
<surname>B&#xf6;rzsei</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>B&#xe1;nhegyi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Asghar</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hudhud</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>In Silico, In Vitro and In Vivo Pharmacodynamic Characterization of Novel Analgesic Drug Candidate Somatostatin SST4 Receptor Agonists</article-title>. <source>Front Pharmacol.</source> <volume>11</volume>, <fpage>601887</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.601887</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lovren&#x10d;i&#x107;</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Matak</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lackovi&#x0107;</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Association of Intranasal and Neurogenic Dural Inflammation in Experimental Acute Rhinosinusitis</article-title>. <source>Front Pharmacol.</source> <volume>11</volume>, <fpage>586037</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.586037</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tarjanyi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tothfalusi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bartykowszki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Szekely</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Largely Accelerated Arterial Aging in Rheumatoid Arthritis Is Associated With Inflammatory Activity and Smoking in the Early Stage of the Disease</article-title>. <source>Front Pharmacol.</source> <volume>11</volume>, <fpage>523962</fpage>&#x2013;<lpage>120099</lpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.601344</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>N&#xf3;gr&#xe1;d</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ny&#x00FA;l-T&#x00F3;th</surname>
<given-names>&#x00C1;.</given-names>
</name>
<name>
<surname>Kozma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moln&#x00E1;r</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Patai</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sikl&#x00f3;s</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Upregulation of Nucleotide-Binding Oligomerization Domain-, LRR- and Pyrin Domain-Containing Protein 3 in Motoneurons Following Peripheral Nerve Injury in Mice</article-title>. <source>Front Pharmacol.</source> <volume>11</volume>, <fpage>584184</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.584184</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sz&#xf6;ll&#x151;si</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Ol&#xe1;h</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lisztes</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Griger</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>T&#x00F3;th</surname>
<given-names>B. I.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk</article-title>. <source>Front Pharmacol.</source> <volume>13</volume>, <fpage>745658</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.745658</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tulb&#x103;</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Popescu</surname>
<given-names>B. O.</given-names>
</name>
<name>
<surname>Manole</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>B&#x103;icu&#x015B;</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Immune Axonal Neuropathies Associated With Systemic Autoimmune Rheumatic Diseases</article-title>. <source>Front Pharmacol.</source> <volume>12</volume>, <fpage>610585</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.610585</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>H. X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J. Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The Protective Role of Immunomodulators on Tissue-Type Plasminogen Activator-Induced Hemorrhagic Transformation in Experimental Stroke: A Systematic Review and Meta-Analysis</article-title>. <source>Front Pharmacol.</source> <volume>11</volume>, <fpage>615166</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.615166</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>